Disruption of BASIGIN decreases lactic acid export and sensitizes non-small cell lung cancer to biguanides independently of the LKB1 status

Oncotarget

Volumn 6, Issue 9, 2015, Pages 6708-6721

  Granja, Sara ^a,b   Marchiq, Ibtissam ^c   Le Floch, Renaud ^c   Moura, Conceição Souto ^e,f   Baltazar, Fátima ^a,b   Pouysségur, Jacques ^c,d  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c CENTRE ANTOINE LACASSAGNE   (France)

^d CENTRE SCIENTIFIQUE DE MONACO   (Monaco)

^e Universidade do Porto   (Portugal)

^f University of Porto   (Portugal)

Author keywords

BASIGIN; CD147; Glycolytic metabolism; Lactate; Lung cancer; MCTs; Metformin; Monocarboxylate transporters; ZFNs

Indexed keywords

BIGUANIDE DERIVATIVE; CD147 ANTIGEN; LACTIC ACID; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 4; PHENFORMIN; PROTEIN KINASE LKB1; ZINC FINGER NUCLEASE; ANTINEOPLASTIC AGENT; BSG PROTEIN, HUMAN; COTRANSPORTER; METFORMIN; MONOCARBOXYLATE TRANSPORT PROTEIN 1; MONOCARBOXYLATE TRANSPORTER; MUSCLE PROTEIN; PROTEIN SERINE THREONINE KINASE; SLC16A4 PROTEIN, HUMAN; STK11 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL MIGRATION; CELL RESPIRATION; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; FEMALE; GLYCOLYSIS; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; UPREGULATION; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; DRUG EFFECTS; DRUG SCREENING; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROTEIN TRANSPORT; TIME FACTOR; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD147; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; GLYCOLYSIS; HUMANS; LACTIC ACID; LUNG NEOPLASMS; METFORMIN; MICE, NUDE; MONOCARBOXYLIC ACID TRANSPORTERS; MUSCLE PROTEINS; PHENFORMIN; PROTEIN TRANSPORT; PROTEIN-SERINE-THREONINE KINASES; SYMPORTERS; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84927127315     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2862     Document Type: Article

References (42)

1. Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat chem biol 2012; 8: 839-847.
2. Bayley JP, Devilee P. The Warburg effect in 2012. Curr Opin Oncol 2012; 24: 62-67.
3. Brahimi-Horn MC, Bellot G, Pouyssegur J. Hypoxia and energetic tumour metabolism. Curr Opin Genet Dev 2011; 21: 67-72.
4. Chen L, Pan Y, Gu L, Nie Z, He B, Song G et al. ERK1/2 signalling pathway is involved in CD147-mediated gastric cancer cell line SGC7901 proliferation and invasion. Exp Biol Med (Maywood). 2013; 238: 903-912.
5. Cioce M, Valerio M, Casadei L, Pulito C, Sacconi A, Mori F et al. Metformin-induced metabolic reprogramming of chemoresistant ALDHbright breast cancer cells. Oncotarget 2014; 5: 4129-4143.
6. Dykens JA, Jamieson J, Marroquin L, Nadanaciva S, Billis PA, Will Y. Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol Appl Pharmacol 2008; 233: 203-210.
7. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893-2917.
8. Gillies RJ, Gatenby RA. Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? JJ Bioenerg Biomembr. 2007; 39: 251-257.
9. Grass GD, Bratoeva M, Toole BP. Regulation of invadopodia formation and activity by CD147. J Cell Sci 2012; 125: 777-788.
10. Halestrap AP. The SLC16 gene family-structure, role and regulation in health and disease. Mol Aspects Med 2013; 34: 337-349.
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
12. Huang Z, Wang L, Wang Y, Zhuo Y, Li H, Chen J et al. Overexpression of CD147 contributes to the chemoresistance of head and neck squamous cell carcinoma cells. J Oral Pathol 2013; 42: 541-546.
13. Kang MJ, Kim HP, Lee KS, Yoo YD, Kwon YT, Kim KM et al. Proteomic analysis reveals that CD147/EMMPRIN confers chemoresistance in cancer stem cell-like cells. Proteomics 2013; 13: 1714-1725.
14. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer res 2006; 66: 8927-8930.
15. Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J 2000; 19: 3896-3904.
16. Koukourakis MI, Giatromanolaki A, Bougioukas G, Sivridis E. Lung cancer: a comparative study of metabolism related protein expression in cancer cells and tumor associated stroma. Cancer Biol Ther 2007; 6: 1476-1479.
17. Le Floch R, Chiche J, Marchiq I, Naiken T, Ilc K, Murray CM et al. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. PNAS 2011; 108: 16663-16668.
18. Lin YC, Wu MH, Wei TT, Lin YC, Huang WC, Huang LY et al. Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress. Oncotarget 2014; 5: 298-308.
19. Marchiq I, Le Floch R, Roux D, Simon MP, Pouyssegur J. Genetic Disruption of Lactate/H+ Symporters (MCTs) and their Subunit CD147/BASIGIN Sensitizes Glycolytic Tumor Cells to Phenformin. Cancer res 2014.
20. Meijer TW, Schuurbiers OC, Kaanders JH, Looijen-Salamon MG, de Geus-Oei LF, Verhagen AF et al. Differences in metabolism between adeno-and squamous cell non-small cell lung carcinomas: spatial distribution and prognostic value of GLUT1 and MCT4. Lung cancer 2012; 76: 316-323.
21. Miranda-Goncalves V, Honavar M, Pinheiro C, Martinho O, Pires MM, Pinheiro C et al. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro-oncol 2013; 15: 172-188.
22. Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, Kikuchi M. Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 2006; 56: 359-367.
23. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000; 348 Pt 3: 607-614.
24. Parks SK, Chiche J, Pouyssegur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer 2013; 13: 611-623.
25. Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L et al. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch. 2008; 452: 139-146.
26. Pinheiro C, Reis RM, Ricardo S, Longatto-Filho A, Schmitt F, Baltazar F. Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol. 2010; 2010: 427694.
27. Pinheiro C, Sousa B, Albergaria A, Paredes J, Dufloth R, Vieira D et al. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol Histopathol 2011; 26: 1279-1286.
28. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F. Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr 2012; 44: 127-139.
29. Pollak M. Potential applications for biguanides in oncology. J Clin Invest 2013; 123: 3693-3700.
30. Poole RC, Halestrap AP. Interaction of the erythrocyte lactate transporter (monocarboxylate transporter 1) with an integral 70-kDa membrane glycoprotein of the immunoglobulin superfamily. J Biol Chem. 1997; 272: 14624-14628.
31. Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nat 2012; 491: 364-373.
32. Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer cell 2013; 23: 143-158.
33. Sidhu SS, Nawroth R, Retz M, Lemjabbar-Alaoui H, Dasari V, Basbaum C. EMMPRIN regulates the canonical Wnt/beta-catenin signaling pathway, a potential role in accelerating lung tumorigenesis. Oncogene 2010; 29: 4145-4156.
34. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
35. Tang X, Lucas JE, Chen JL, LaMonte G, Wu J, Wang MC et al. Functional interaction between responses to lactic acidosis and hypoxia regulates genomic transcriptional outputs. Cancer res 2012; 72: 491-502.
36. Travis W BE, Muller-Hermelink H, Harris C. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. IARC Press World Heal Organ Classif Tumors 2004; 10.
37. Weidle UH, Scheuer W, Eggle D, Klostermann S, Stockinger H. Cancer-related issues of CD147. Cancer Genomics Proteomics 2010; 7: 157-169.
38. Wilson MC, Meredith D, Fox JE, Manoharan C, Davies AJ, Halestrap AP. Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4: the ancillary protein for the insensitive MCT2 is EMBIGIN (gp70). J Biol Chem 2005; 280: 27213-27221.
39. Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, Parslow D et al. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol. 2007; 292: C125-136.
40. Yan L, Zucker S, Toole BP. Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost. 2005; 93: 199-204.
41. Zhao S, Chen C, Liu S, Zeng W, Su J, Wu L et al. CD147 promotes MTX resistance by immune cells through up-regulating ABCG2 expression and function. J Dermatol Sci 2013; 70: 182-189.
42. Zhou S, Liao L, Chen C, Zeng W, Liu S, Su J et al. CD147 mediates chemoresistance in breast cancer via ABCG2 by affecting its cellular localization and dimerization. Cancer Lett. 2013; 337: 285-292.